Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy…

By B. D. de Pauw, Thomas J. Walsh, J. P. Donnelly, David A. Stevens, John E. Edwards, Thierry Calandra, Peter G. Pappas, J. Maertens, O. Lortholary, Carol A. Kauffman and 22 more. Clinical Infectious Diseases, 2008

4,849 citations recorded by the source corpus.

Subfields: Epidemiology, Infectious Diseases, Small Animals

View Paper: https://www.semanticscholar.org/paper/70de3c804e200b7e4baa037a85ca7957973cc9c2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. Trish Perl
2. M. Arendrup
3. D. Kontoyiannis
4. Thierry Calandra
5. E. Anaissie
6. M. Pfaller
7. D. Diekema

In Infectious Diseases

1. M. Arendrup
2. D. Kontoyiannis
3. Trish Perl
4. J. Fishman
5. E. Anaissie
6. M. Pfaller
7. D. Diekema

In Small Animals

1. E. Anaissie
2. D. Kontoyiannis

Citations in the corpus

• Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. (2011, methodology): “For the classification of each case as proven or probable, the revised definitions of invasive fungal disease of the European Organization for Research and Treatment of Cancer/Mycosis Study Group (EORTC/MSG) were used [16], with the following modification: if the diagnosis was made by histology and ”
• Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). (2010, methodology): “Many of these reports emphasize especially high incidence rates of specific infections in certain transplant types [8, 11, 14, 15, 19, 20].”
• Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. (2018, background): “These patients frequently do not fulfil the EORTC/MSG criteria for invasive aspergillosis [169].”
• Histopathologic Diagnosis of Fungal Infections in the 21st Century (2011, background): “An international consensus defining proven, probable, and possible invasive fungal infections for research purposes was published in 2002 and revised in 2008 (7, 43).”
• ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients (2016, result): “Integration of the results of baseline galactomannan detection tests performed after primary analysis and re-categorization according to the 2008 EORTC/MSG definition criteria allowed more mycologically documented cases of invasive aspergillosis to be identified.(49) Conclusions of this post-hoc ana”
• Epidemiology and clinical manifestations of mucormycosis. (2012, background): “Patients are often treated presumptively for mucormycosis, but cases may be missed due to lack of histological and microbiological proof [22].”
• Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “defining IFIs, including IA, require a microbiologic and/or histopathologic diagnosis to define proven infection [64].”
• Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplant Recipients: A Global Perspective (2009, background): “For HCT centers with high CLABSI rates (more than 1 per 1000 catheter days) despite effective implementation of the CLABSI bundle elements, use of additional interventions, such as minocycline/rifampin antimicrobial-impregnated catheters, to prevent CLABSIs should be considered (BIII) [182].”